What we do

Commit Biologics has developed a novel platform technology to harness the power of the complement system, a vital part of the innate immune system. With a unique mechanism of action, our technology has the potential to create a new type of treatment for a variety of cancers and autoimmune diseases.

Our BiCE™ technology

The complement system represents an efficient immune mechanism for clearing pathogens, maintaining homeostasis and for stimulating an adaptive immune response. However, complement is inherently difficult to activate and is currently underexploited in treatment of both cancer and autoimmune disease.

Our Bispecific Complement Engaging  technology (BiCE™) is designed to potently activate the complement system to induce highly-selective killing of tumor cells or cells implicated in autoimmune disease. BiCE™ uses single domain antibodies that bind to the complement protein C1q, consequently directing the complement system in a highly targeted way against cells of interest. With a novel mechanism of action, the technology has the potential to redefine the treatment of cancer and autoimmune disease.

Commit is using established antibodies as a basis for developing best-in-class therapeutics, thus cutting development times and reducing risk.

While antibody drug conjugates, T-cell engagers and CAR-Ts have made important advances in recent years, these approaches can be limited by toxicities, specific target density considerations, and - with T-cell directed therapies – T-cell exhaustion. Our BiCE™ technology can potentially address these limitations to enable the development of effective therapeutic options for the treatment of cancer and autoimmune diseases.

The complement system is part of the body’s immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defense, begins with the engagement of C1q to antibodies that coat the cell surface and initiating multiple effector functions that leads cell killing.
 
However, current monoclonal antibodies developed for therapeutic purposes have inherent restraints that hinder effective engagement of C1q, thus limiting complement activation and its mediated effector functions.

Commit’s BiCE™ technology was developed to overcome the limitations of conventional monoclonal antibodies, to harness the power of the complement system and direct it towards tumor and immune cells for therapeutic applications. Unleashing this power in a highly targeted way with Commit’s technology potentially allows for a broad therapeutic index and the development of highly effective treatments.